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Abstract
Background: Atrial fibrillation (AF) after thoracic surgery is a continuing source of morbidity and mortality. The
effect of postoperative AF on long-term survival however has not been studied. Our aim was to evaluate the
impact of AF on early outcome and on survival > 5 years after pulmonary lobectomy for lung cancer.
Methods: From 1996 to June 2009, 454 consecutive patients undergoing lobectomy for lung cancer were enrolled
and followed-up until death or study end (October 2010). Patients with postoperative AF were identified; AF was
investigated with reference to its predictors and to short- and long-term survival (> 5 years).
Results: Hospital mortality accounted for 7 patients (1.5%), while postoperative AF occurred in 45 (9.9%). Independent
AF predictors were: preoperative paroxysmal AF (odds ratio [OR] 5.91; 95%CI 2.07 to 16.88), postoperative blood
transfusion (OR 3.61; 95%CI 1.67 to 7.82) and postoperative fibro-bronchoscopy (OR 3.39; 95%CI 1.48 to 7.79). Patients
with AF experienced higher hospital mortality (6.7% vs. 1.0%, p = 0.024), longer hospitalization (15.3 ± 10.1 vs. 12.2 ± 5.2
days, p = 0.001) and higher intensive care unit admission rate (13.3% vs. 3.9%, p = 0.015). The median follow-up was 36
months (maximum: 179 months). Among the 445 discharged subjects with complete follow-up, postoperative AF was
not an independent predictor of mortality; however, among the 151 5-year survivors, postoperative AF independently
predicted poorer long-term survival (HR 3.75; 95%CI 1.44 to 9.08).
Conclusion: AF after pulmonary lobectomy for lung cancer, in addition to causing higher hospital morbidity and
mortality, predicts poorer long-term outcome in 5-year survivors.
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Background
Atrial fibrillation (AF) remains the most common medical
complication after thoracic surgery, with an incidence ran-
ging from 10% to 20% after pulmonary lobectomy, and as
much as 40% after pneumonectomy [1-7]. Postoperative AF
has been shown to predict worse prognosis, being corre-
lated with higher hospital morbidity and mortality and with
a considerable increase of hospital stay and cost [1-6]. How-
ever, the prognostic implications of this arrhythmia after
pulmonary lobectomy for lung cancer remain controversial.
None of the studies examining the consequences of
postoperative AF has managed to present compelling data
supporting an independent association between this
arrhythmia and late mortality, because postoperative survi-
val was examined only up to 36 months [4,5].
The primary aim of this study was to assess the
impact of AF on early outcome and on survival > 5
years from pulmonary lobectomy for lung cancer. Fac-
tors associated with AF development after lobectomy
were also investigated.
Materials and methods
Population and study design
Between January 1996 and June 2009, 473 consecutive
patients undergoing lobectomy for primary lung cancer
at Varese University Hospital were considered for this
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study; none of the operations was an emergency. Of
these patients 19 were excluded from analysis because
they had chronic AF (n = 8), pace-maker devices (n =
4), or incomplete data (n = 7). Patients with a history of
paroxysmal AF, but in sinus rhythm at operation, were
included [3]. The final study cohort comprised 454
patients (81.3% male), with mean age of 65.4 ± 8.8 years
(range 28 to 84). Patient characteristics are listed in
Table 1.
Throughout the study period the patients’ data were pro-
spectively recorded in a computerized database. The latter
included information about demographics, comorbidities,
medical and surgical history, preoperative respiratory and
cardiac testing, operative details and postoperative events
during the hospital stay (Table 1 and 2). After discharge,
follow-up was conducted according to the American Col-
lege of Chest Physicians (ACCP) guidelines [8], with physi-
cal examination and imaging study (chest x-rays (CXR) or
computed tomography (CT)) every 6 months for 2 years
and then annually. For patients who died during follow-up,
the date of death was recorded. For patients lost to follow-
up, the vital status were ascertained at the end of study, by
linkage with the Lombardy Region Health System Registry.
The vital status of residents outside this region were ascer-
tained by contacting family members or the respective gen-
eral practitioner. Survival follow-up was closed on October
30, 2010.
With the aim to analyze mortality profile of all dis-
charged patients, we recorded the cause of death by
linkage with the Varese Province Mortality Registry. The
cause of death was classified by disease groups, accord-
ing to the International Classification of Diseases, Edi-
tion IX (ICD-IX) as follows: cardiovascular diseases
(ICD-IX: 390-459); lung cancer (ICD-IX: 162.2-162.9);
all cancers other than lung cancer (ICD-IX:140-162.0,
163-239); all other causes of deaths.
Table 1 Patient characteristics
Predictora All patients
(n = 454)
Patients without AF
(n = 409)
Patients
with AF
(n = 45)
p Value
Demographic
Mean age, year 65.4 ± 8.8 65.0 ± 8.9 68.6 ± 6.8 0.008
Male, n (%) 369 (81.3) 332 (81.2) 37 (82.2) 0.864
BMI, kg/m2 25.6 ± 4.1 25.7 ± 4.2 24.7 ± 3.3 0.116
Comorbidities
Paroxysmal AF, n (%) 45 (9.9) 38 (8.8) 7 (15.5) 0.182
CAD, n (%) 56 (12.3) 45 (11.0) 11 (24.4) 0.009
Prior AMI, n (%) 15 (3.3) 12 (2.9) 3 (6.7) 0.178
Hypertension, n (%) 183 (40.3) 161 (39.4) 22 (48.9) 0.216
Diabetes, n (%) 58 (12.8) 53 (13.0) 5 (11.1) 0.999
Dyslipidemia, n (%) 71 (15.6) 60 (14.7) 11 (24.4) 0.087
Current smokers, n (%) 182 (40.1) 164 (40.1) 18 (40.0) 0.990
PVD, n (%) 115 (25.3) 106 (25.9) 9 (20.0) 0.386
CVA, n (%) 19 (4.2) 16 (3.9) 3 (6.7) 0.421
Baseline biochemical data
Creatinine, mg/dL 1.0 ± 0.5 1.0 ± 0.4 1.2 ± 1.1 0.287
Hb, g/dL 13.8 ± 1.6 13.8 ± 1.5 13.6 ± 1.8 0.352
Baseline respiratory data
FEV1, % of predicted 88.1 ± 21.9 88.2 ± 21.7 86.9 ± 24.1 0.716
PaO2, mmHg 94.5 ± 21.9 94.3 ± 20.9 96.3 ± 29.2 0.558
Preoperative therapy
b-blockers, n (%) 36 (7.9) 29 (7.1) 7 (15.6) 0.046
Calcium antagonists, n (%) 58 (12.8) 51 (12.5) 7 (15.6) 0.556
ACE-Inhibitors, n (%) 67 (14.8) 59 (14.4) 8 (17.8) 0.547
ARBs, n (%) 33 (7.3) 29 (7.1) 4 (8.9) 0.659
Statins, n (%) 45 (9.9) 39 (9.5) 6 (13.3) 0.429
Neoadjuvant chemotherapy, n (%) 30 (6.6) 28 (6.8) 2 (4.4) 0.756
a For continuous variables, mean ± SD (standard deviation); for categorical variables, number (percent)
ACE angiotensin converting enzyme, AF atrial fibrillation, AMI acute myocardial infarction, ARB angiotensin receptor blocker, BMI body mass index, CAD coronary
artery disease, CVA cerebrovascular accident, FEV1 forced expiratory volume in 1 second, Hb haemoglobin, PaO2 partial arterial oxygen pressure, PVD peripheral
vascular disease
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The protocol of this study was in compliance with the
local Institutional Review Board and received full
approval. Written informed consent was obtained from
the participants of this study.
Patient management
All patients underwent preoperative clinical cardiologic
and anesthesiologic evaluation, CXR and CT, and pul-
monary function tests. Preoperative medications, includ-
ing b-blockers, diuretics, antihypertensives, statins, and
calcium-channel blockers were routinely omitted on the
day of the operation and were restarted on postoperative
day one, unless clinically contraindicated. Operability was
determined according to established guidelines for
lobectomy [9,10]. All pulmonary resections were per-
formed by open thoracotomy, by the same thoracic
surgical team throughout the study period. Standardized
surgical approach and anesthesiologic management were
used and remained constant during the study. Briefly,
short-term antibiotic prophylaxis was routinely adminis-
tered intravenously (ampicillin/sulbactam 3 gr) before
anaesthesia. An epidural catheter for postoperative pain
relief was offered to all patients and premedication with
midazolam was done before induction of general anaes-
thesia. After administration of rocuronium bromide
(0.15 mg/kg) and orotracheal intubation with double-
lumen tube, anaesthesia was maintained by 50% O2 and
2% sevoflurane. Mediastinal sampling lymphadenectomy
was routinely performed. Pathological lung cancer sta-
ging was assessed according to the 1997 TNM classifica-
tion [11]. Two chest tubes were placed on water seal at
the end of the operation and removed when no air leaks
Table 2 Peri- and post-operative data
Predictora Patients without AF
(n = 409)
Patients
with AF
(n = 45)
p Value
Lung cancer characteristics
Cancer location, n (%) 0.011
Right lung 236 (57.7) 17 (37.8)
Left lung 173 (42.3) 28 (62.2)
UICC Stage, n (%)b 0.568
Stage I 211 (54.0) 24 (54.5)
Stage II 86 (22.0) 7 (15.9)
Stage III/IV 94 (24.0) 13 (29.5)
Histology, n (%) 0.281
Squamous cell ca 140 (34.2) 21 (46.7)
Adenocarcinoma 209 (51.1) 21 (46.7)
Large cell 24 (5.9) 1 (2.2)
Other 36 (8.8) 2 (4.4)
Perioperative data
PaO2, mmHg 85.3 ± 30.8 86.9 ± 16.3 0.729
Ventilation time, h 3.2 ± 0.7 3.2 ± 0.7 0.540
Inotropes, n (%) 23 (5.6) 2 (4.4) 0.999
Blood transfusions, n (%) 36 (8.8) 13 (28.9) < 0.001
Postoperative data
Reoperation for bleeding, n (%) 3 (0.7) 0 (0) 0.999
FBS, n (%) 31 (7.1) 13 (24.4) < 0.001
AMI, n (%) 2 (0.5) 2 (4.4) 0.051
CVA, n (%) 7 (1.7) 2 (4.4) 0.221
AKI, n (%) 14 (3.4) 3 (6.7) 0.232
Respiratory failure, n (%) 3 (0.7) 5 (11.1) < 0.001
Pneumonia, n (%) 5 (1.2) 2 (4.4) 0.146
Length of stay, days 12.2 ± 5.2 15.3 ± 10.1 0.001
ICU admission n (%) 16 (3.9) 6 (13.3) 0.015
Hospital Mortality n (%) 4 (1.0) 3 (6.7) 0.024
a For continuous variables, mean ± SD (standard deviation); for categorical variables, number (percent)
b UICC stage [11] not available for the 19 (4.2%) patients with tumor type other than NSCLC
AKI acute kidney injury (according RIFLE criteria), AMI acute myocardial infarction, CVA cerebrovascular accident (stroke + transient ischemic attack), FBS
fibrobronchoscopy, ICU intensive care unit, PaO2 partial arterial oxygen pressure, UICC Union International Contre le Cancer
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were present and pleural drainage output was < 150 mL/
24 h. Postoperative pain control was achieved mainly by
epidural analgesia and/or by systemic opioids combined
with non-steroidal anti-inflammatory drugs. Low mole-
cular weight heparin was administered for 2-4 weeks
postoperatively.
After surgery patients were transferred to a general
intensive care unit (ICU) for the first 12/24 hours. Heart
rate, electrocardiography (ECG), central venous and
arterial pressures, and acid-base blood gases were con-
tinuously monitored during the ICU stay. Inotropic sup-
port was provided if the ventricular contractility was
markedly impaired. Perioperative need of blood products
was determined on an individual, patient-by-patient
basis; in general, blood transfusions were administered
when haemoglobin was < 8 g/dL. Postoperative fibro-
bronchoscopy (FBS) was performed in case of lung
atelectasis, and in order to obtain bronchial secretion
samples for microbiological examinations. All patients
had an active program of postoperative physiotherapy
including deep-breathing exercises.
AF monitoring and definition
Cardiac rhythm assessment followed the daily practice of
an integrated clinic encompassing ICU and ward level,
sharing the same routines and data collection system.
Patients were monitored by continuous ECG during a
minimum of 48 hours postoperatively. Subsequent moni-
toring was by repeated daily observations by nurses and
physicians, at least every 2 hours. In case of rhythm dis-
turbance reported by nurse or patient, a 12-lead ECG
recording was obtained, and continuous ECG monitoring
was restarted if necessary. Additional recordings were
collected at clinical suspicion of AF. The arrhythmia was
defined by physician assessment, on the basis of a teleme-
try strip or a 12-lead ECG recording. Amiodarone, either
orally or intravenously administered, constituted the
standard pharmacological treatment of AF. Digoxin was
administered if necessary to reduce high ventricular rate.
In case of AF recurrence, the same protocol was applied.
In this study the definition of postoperative AF includes
the successfully treated AF as well as AF persistent at
discharge.
Statistical analysis
Extracted database variables were tabulated using Micro-
soft Excel® (Microsoft Corp, Redmond, WA) and statisti-
cal analysis was computed using SPSS, release 16.0 for
Windows® (SPSS Inc., Chicago, IL). Continuous variables
were tested for normal distribution by the Kolmogorov-
Smirnov test and compared between groups with unpaired
Student’s t test for normally distributed values; otherwise,
the Mann-Whitney U test was employed. In case of
dichotomous variables, group differences were examined
by chi-square or Fisher exact tests as appropriate.
A stepwise logistic regression model was developed to
identify variables predicting postoperative AF. The model
was built with univariable predictors of AF with p value ≤
0.15. The stepwise approach was confirmed by backward
and forward methods. The strength of the association of
variables with the dependent one was estimated by calcu-
lating the odds ratio (OR) and 95% confidence intervals
(CI). The model was calibrated by the Hosmer-Lemeshow
goodness-of-fit test, while model discrimination was evalu-
ated by using the area under the receiver operating charac-
teristic (ROC) curve.
Kaplan-Meier estimates and log-rank test were per-
formed for the postoperative mortality rate comparison of
patients with or without postoperative AF. Mortality
hazard ratios (HRs) were generated by a multivariable Cox
regression analysis, using univariable Cox predictors with
p < 0.15 (Table 3). Patients who died within 30 days of
operation were excluded from the final analysis of survival.
A p value < 0.05 was considered statistically signifi-
cant. Results are expressed as mean ± standard deviation
(SD) for continuous variables and frequencies for the
categorical ones.
Results
AF and early outcome
Hospital mortality accounted for 7 (1.5%) subjects, while
AF occurred in 9.9% of patients (45 of 454) and its fre-
quency peaked on the second postoperative day (69% of
cases). Mean AF duration was 9.2 ± 7.1 hours (range: 1-
24). Of the 45 patients with postoperative AF, 29 (64%)
had a single arrhythmia episode, while 16 (35%) experi-
enced multiple episodes. Among the 45 patients with post-
operative AF, 27 (60%) were treated by amiodarone, 7
(16%) by digoxin, 4 (9%) by calcium-channel blocker, and
2 (4%) by beta-blocker. The remained 5 patients were trea-
ted with a simple correction of the electrolyte imbalance
(potassium). In all cases the choice of medication was
based on Cardiologist prescription. At discharge, persistent
AF was present in 2 of 45 (4.4%) patients.
Patients with AF compared to patients without it were
older and more frequently had a history of paroxysmal
AF or coronary artery disease (p = 0.008, p < 0.001 and
p = 0.009, respectively) (Table 1). Other comorbidities,
pulmonary function tests and preoperative medications,
with the exception of b-blocker agents, did not reveal
significant differences between patients with AF and
without it. No correlation was observed between post-
operative AF and neo-adjuvant chemotherapy, lung can-
cer stage and histological type of cancer (p = 0.756, p =
0.568, p = 0.281 respectively). Subjects with cancer loca-
tion in the left lung were more frequently affected by
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AF (p = 0.011). Postoperatively, patients with AF had a
higher prevalence of respiratory failure (p < 0.001), of
postoperative FBS (p < 0.001) and required more fre-
quently blood transfusions (p < 0.001). Moreover,
patients with AF had longer hospital stay (p = 0.001),
higher ICU admission rate (p = 0.015), and higher hos-
pital mortality (p = 0.024) (Table 2).
At multivariate analysis, independent predictors of
postoperative AF were preoperative paroxysmal AF (OR
5.91, 95%CI 2.07 to 16.88), need of peri-operative blood
transfusion (OR 3.61, 95%CI 1.67 to 7.82), and post-
operative FBS (OR 3.39; 95%CI 1.48 to 7.79). The Hos-
mer-Lemeshow goodness-of-fit test (c2 [1 d.f.] = 0.61,
p = 0.433) and ROC analysis (AUC of 0.70) revealed
good calibration and discrimination for the multivariate
analysis.
AF and late survival
Follow-up was completed for 445/447 (99.6%) patients
discharged after resection, with median follow-up of 36
months (maximum: 179 months). Kaplan-Meier analysis
of subjects without AF revealed 1-, 5- and 10-year over-
all survival of 99%, 49% and 34%, respectively, similar to
98%, 42%, and 31% survival of patients with AF (p =
0.085) (Figure 1).
At multivariable Cox regression analysis of 445 dis-
charged patients with complete follow-up, postoperative
AF was not an independent predictor of late mortality
(HR 1.17; 95%CI 0.76 to 1.79), while independent predic-
tors were: lung cancer UICC stage (HR 2.09; 95%CI 1.60
to 2.74), diabetes (HR 1.64; 95%CI 1.17 to 2.29), male gen-
der (HR 1.51; 95%CI 1.07 to 2.13), and age (HR 1.02; 95%
CI 1.00 to 1.04) (Table 4). Among the 151 patients alive at
5 years from cancer resection, the multivariable Cox
regression analysis revealed that postoperative AF was the
strongest independent predictor (HR 3.75; 95%CI 1.44 to
9.81) along with forced expiratory volume in 1 second
(FEV1) < 80% of predicted (HR 2.07; 95%CI 1.09 to 3.93)
(Table 4).
Among the 445 discharged subjects with complete fol-
low-up, death from cardiovascular diseases occurred
more frequently in patients affected by postoperative AF
than in those without it (21% vs.10%, p = 0.073).
Among 151 5-year survivors, a similar difference of
Figure 1 Kaplan-Meier survival curves of patients with atrial
fibrillation (AF) and without AF (No AF).
Table 3 Univariable Cox Predictors of postoperative
mortality
Variable OR 95%CI p Value
Demographic
Age, years 1.02 1.01 - 1.03 0.042
Female 0.68 0.48 - 0.95 0.025
BMI, kg/m2 0.98 0.94 - 1.02 0.256
Cardiac data
Paroxysmal AF 1.74 1.01 - 2.98 0.044
CAD 1.76 0.93 - 3.31 0.080
Prior AMI 1.41 0.98 - 2.01 0.061
Comorbidities
Hypertension 1.12 0.87 - 1.43 0.387
Diabetes 1.73 1.23 - 2.41 0.001
Dyslipidemia 1.21 0.83 - 1.76 0.326
COPD 0.99 0.77 - 1.27 0.931
Current smokers 1.27 0.99 - 1.64 0.064
PVD 1.03 0.77 - 1.37 0.836
Preop CVA 1.41 0.79 - 2.51 0.249
CRF 1.17 0.29 - 4.70 0.826
Other data
Creatinine (basal), mg/dL 1.20 0.89 - 1.62 0.216
Hb, g/dL 0.95 0.88 - 1.03 0.210
FEV1 < 80% 0.74 0.58 - 0.96 0.025
Cancer characteristics
Right Lobectomy 1.16 0.91 - 1.48 0.235
Neoadjuvant chemotherapy 1.04 0.62 - 1.75 0.884
Stage UICCa 1.96 1.52 - 2.53 < 0.001
Histologyb 0.91 0.71 - 1.16 0.452
Postoperative Data
Inotropes 1.79 0.98 - 3.29 0.060
Blood transfusion 1.51 1.02 - 2.22 0.037
FBS 1.11 0.69 - 1.78 0.658
Postop AMI 1.98 0.28 - 14.18 0.493
Postop CVA 3.26 1.45 - 7.35 0.004
AKI 1.17 0.62 - 2.20 0.632
POPAF 1.41 0.95 - 2.09 0.087
a Classes I and II vs. classes III and IV (class I and II as a reference group)
b Adenocarcinoma vs. others carcinoma (others as a reference group)
AKI acute kidney injury, AF atrial fibrillation, AMI acute myocardial infarction,
BMI body mass index, CAD coronary artery disease, COPD chronic obstructive
pulmonary disease, CRF chronic renal failure, CVA cerebrovascular accident,
FBS fibrobronchoscopy, FEV1 forced expiratory volume in 1 second, Hb
hemoglobin, POPAF postoperative atrial fibrillation, PVD peripheral vascular
disease, UICC Union International Contre le Cancer.
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cardiovascular disease mortality was also observed (40%
vs. 21%, p = 0.336).
Discussion
Despite improvements in surgical and anesthesiological
techniques, the incidence of AF after thoracic surgery has
remained substantially unchanged over the past two dec-
ades [1-7]. Although several studies have analysed the risk
factors for this arrhythmia and possible preventive strate-
gies, its exact pathophysiology has not been elucidated yet.
Few data are available regarding the impact of AF on sur-
vival after thoracic surgery [4-7]. Our study confirms the
negative impact of AF on hospital mortality after lobect-
omy for lung cancer; in addition, it provides the first evi-
dence that patients with postoperative AF who survive
5 years have a significantly reduced long-term survival.
Our data also identified preoperative paroxysmal AF,
postoperative FBS and blood transfusions as independent
predictors of postoperative AF. While paroxysmal AF and
transfusion requirement are well-known AF risk factors,
because of the electrical and histological abnormalities of
patient atrial tissue and because of the amplified inflam-
matory response associated with transfusion of blood
components [2,12-14], the correlation between postopera-
tive FBS and AF has not been reported previously. A pos-
sible explanation of such correlation is the peri-operative
stress of the FBS procedure, resulting in a hyperadrenergic
state with increased levels of catecholamines. The latter
enhance triggered activity and automaticity, which are key
factors in the development of atrial arrhythmia [15,16].
An intriguing observation of the present study was an
increased AF occurrence in patients undergoing left
lobectomy compared with those subjected to right one
(62% vs. 38%). A plausible reason could be related to the
increased manipulation and increased trauma of the left
cardiac structures (left atrial auricular and left pulmonary
vein) [17]. However, this statistical relationship was not
confirmed at multivariable level.
Our data confirm that AF following lobectomy for
lung cancer increases early postoperative mortality and
causes significant adverse effects, prolonging the length
of ICU and hospital stay [2-4]. Postoperative AF was
here associated with three- to six-fold increased risk of
both hospital mortality and ICU admission, and with
two- to three-day increase in total hospital length.
A relevant finding of our study was the negative impact
of postoperative AF on long-term survival. Previous inves-
tigations on the subject focused on the peri-operative per-
iod and failed to include the analysis of long-term survival,
because postoperative follow-up was interrupted after
about 3 years [4,5]. The association between postoperative
AF and postoperative survival is controversial [4-6]. Amar
and co-workers [5] first demonstrated that early supraven-
tricular tachydysrhythmias (SVT) were associated with
reduced postoperative survival, in a population of 78
patients with non-small cell lung carcinoma. At the con-
clusion of that study (median follow-up: 17 months), only
1 of 10 patients with SVT was alive, whereas 39 of 68
(57%) who did not develop SVT were alive (p = 0.01) [5].
Murthy and colleagues [6] reported the association of
postoperative AF with increased risk of late adverse out-
comes in 198 patients after esophagectomy. In that case
series, drawn from 921 patients, median survival was
shorter for those affected by AF compared with controls
(11.5 vs. 14.5 months); however, when hospital mortality
was excluded from analysis, survival was not different
(14.5 vs. 16.9 months) [6]. Cardinale and colleagues [4],
after 233 lung cancer operations with a mean follow-up of
18 ± 8 months, recorded no difference of 3-year mortality
between patients with and without AF.
All the above mentioned studies analysing a possible
direct association between postoperative AF and mortality
after thoracic surgery, however, have limitations due to
heterogeneous cancer populations, small sample sizes,
incomplete matching or exclusion of many patients from
analysis, and follow-up not extended beyond three years
[4-6]. Our study had much longer follow-up (median 36;
maximum 179 months). Among 5-year survivors we
found that postoperative AF was an independent predictor
of poor long-term survival.
The mechanisms by which postoperative AF may cause
mortality in later years are difficult to analyze. Despite
attempts to account for confounding mechanisms, it is
possible that AF is associated with mortality because it
usually occurs in patients with a more severe comorbidity
profile [1-3]. Plausible mechanisms supporting a direct
effect of postoperative AF include heart failure and the
potential AF recurrence with attendant thromboembolic
sequelae [18,19].
Our findings are consistent with the data presented by
Groth and co-workers [20]. The risk of dying for lung can-
cer exceeds the risk of dying of cardiovascular disease
Table 4 Independent predictors of postoperative
mortality
Predictor p Value HR 95% CI
In 445 discharged patients
UICC cancer stagea < 0.001 2.09 1.60 - 2.74
Diabetes 0.004 1.64 1.17 - 2.29
Male gender 0.018 1.51 1.07 - 2.13
Ageb 0.021 1.02 1.00 - 1.04
In 151 5-year survivors
Postoperative AF 0.007 3.75 1.44 - 9.81
FEV1 < 80% 0.027 2.07 1.09 - 3.93
a Classes I and II vs. classes III and IV (class I and II as a reference group)
b By one-year increment
CI confidence interval, HR hazard ratio, FEV1 forced expiratory volume in 1
second, UICC Union Internationale Contre le Cancer
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immediately after lung surgery, but this relation dimin-
ished with time. Being postoperative AF a mirror of car-
diac status, an important implications for NSCLC
survivors is the need for a long-term surveillance and pro-
phylaxis of arrhythmias along with the planned lung fol-
low-up.
There are limitations to the present study. Firstly, this
is a single center study and its design is retrospective,
although the data were prospectively collected. Secondly,
the statistical analysis is limited by the large difference
between the number of patients with AF and of those
without it. Thirdly, the association we observed between
AF and late mortality does not necessarily indicate cau-
sation, although studies on the general population
affected by chronic AF and studies reporting the out-
come of cardiac surgery patients with postoperative AF,
revealed a direct AF effect in causing late mortality
[18,21]. In our study subgroup analysis of AF patients
by tumor stage, and by cause of death was not feasible,
due to the small number of subjects in each subgroup.
Similarly, we cannot evaluate the possible role of sys-
tematic mediastinal lymph node dissection, because we
routinely performed mediastinal sampling lymphade-
nectomy. Finally, we did not collect information about
post-discharge AF recurrence, nor did we control for
the effect of drug administration after patient discharge,
due to unreliable information on anti-arrhythmic medi-
cations and long-term use of anticoagulation therapy.
Because of these limitations, the proposed mechanisms
explaining the statistically significant association that we
found between postoperative AF and poorer 5-year sur-
vival remain speculative. Despite these limitations, to
date our study is the largest capturing the late deleter-
ious effects of AF and examining the clinically relevant
question of whether AF after pulmonary lobectomy for
cancer is associated with increased long-term mortality.
Conclusion
Postoperative AF predicts poorer long-term survival in
5-year survivors after pulmonary lobectomy for cancer,
in addition to causing higher hospital morbidity and
mortality. After pulmonary lobectomy for cancer, a
long-term surveillance and prophylaxis of arrhythmia
seem justified.
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International Contre le Cancer.
Author details
1Department of Surgical and Morphological Sciences, Center for Thoracic
Surgery, Varese University Hospital, University of Insubria, Varese, Italy.
2Department of Surgical and Morphological Sciences, Cardiac Surgery Unit,
Varese University Hospital, University of Insubria, Varese, Italy.
Authors’ contributions
AI and LD designed the study, analyzed and interpreted the data and wrote
the manuscript; GM performed the statistical analysis, analyzed the data and
wrote the manuscript; GR contributed to the design the study and
acquisition of data; NR and VC helped to draft the final manuscript and
added important comments to the paper.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 October 2011 Accepted: 10 January 2012
Published: 10 January 2012
References
1. Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D: Risk factors for atrial
fibrillation after lung cancer surgery: analysis of the Society of Thoracic
Surgeons general thoracic surgery database. Ann Thorac Surg 2010,
90:368-374.
2. Vaporciyan AA, Correa AM, Rice DC, Roth JA, Smythe WR, Swisher SG,
Walsh GL, Putnam JB: Risk factors associated with atrial fibrillation after
noncardiac thoracic surgery: analysis of 2588 patients. J Thorac
Cardiovasc Surg 2004, 127:779-786.
3. Roselli EE, Murthy SC, Rice TW, Houghtaling PL, Pierce CD, Karchmer DP,
Blackstone EH: Atrial fibrillation complicating lung cancer resection. J
Thorac Cardiovasc Surg 2005, 130:438-444.
4. Cardinale D, Martinoni A, Cipolla CM, Civelli M, Lamantia G, Fiorentini C,
Mezzetti M: Atrial fibrillation after operation for lung cancer: clinical and
prognostic significance. Ann Thorac Surg 1999, 68:1827-1831.
5. Amar D, Burt M, Reinsel RA, Leung DH: Relationship of early postoperative
dysrhythmias and long-term outcome after resection of non-small cell
lung cancer. Chest 1996, 110:437-439.
6. Murthy SC, Law S, Whooley BP, Alexandrou A, Chu KM, Wong J: Atrial
fibrillation after esophagectomy is a marker for postoperative morbidity
and mortality. J Thorac Cardiovasc Surg 2003, 126:1162-1167.
7. De Decker K, Jorens PG, Van Schil P: Cardiac complications after
noncardiac thoracic surgery: an evidence-based current review. Ann
Thorac Surg 2003, 75:1340-1348.
8. Rubins J, Unger M, Colice GL: Follow-up and surveillance of the lung
cancer patient following curative intent therapy: ACCP evidence-based
clinical practice guideline (2nd edition). Chest 2007, 132:355S-367S.
9. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K: Treatment of
non-small cell lung cancer stage I and stage II: ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S.
10. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW: Treatment of non-
small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice
guidelines (2nd edition). Chest 2007, 132:243S-265S.
11. Mountain CF: Revision in the international system for staging lung
cancer. Chest 1997, 111:1710-1717.
12. Fransen E, Maessen J, Dentener M, Senden N, Buurman W: Impact of blood
transfusions on inflammatory mediator release in patients undergoing
cardiac surgery. Chest 1999, 116:1233-1239.
13. Mariscalco G, Engström KG, Ferrarese S, Cozzi G, Bruno VD, Sessa F, Sala A:
Relationship between atrial histopathology and atrial fibrillation after
coronary bypass surgery. J Thorac Cardiovasc Surg 2006, 131:1364-1372.
14. Goette A, Juenemann G, Peters B, Klein HU, Roessner A, Huth C, Röcken C:
Determinants and consequences of atrial fibrosis in patients undergoing
open heart surgery. Cardiovasc Res 2002, 54:390-396.
15. Mariscalco G, Engström KG: Are current smokers paradoxically protected
against atrial fibrillation after cardiac surgery? Nicotine Tob Res 2009,
11:58-63.
Imperatori et al. Journal of Cardiothoracic Surgery 2012, 7:4
http://www.cardiothoracicsurgery.org/content/7/1/4
Page 7 of 8
16. Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G,
Tonkin AM: Atrial fibrillation after coronary artery bypass grafting is
associated with sympathetic activation. Ann Thorac Surg 1995,
60:1709-1715.
17. Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, Mangano DT,
Browner WS: Atrial fibrillation following coronary artery bypass graft
surgery, predictors, outcomes, and resource utilization. MultiCenter
Study of Perioperative Ischemia Research Group. JAMA 1996, 276:300-306.
18. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P,
Cantore C, Biglioli P, Sala A: Atrial fibrillation after isolated coronary
surgery affects late survival. Circulation 2008, 118:1612-1618.
19. Mariscalco G, Engstrom KG: Postoperative atrial fibrillation is associated
with late mortality after coronary surgery, but not after valvular surgery.
Ann Thorac Surg 2009, 88:1871-1876.
20. Groth SS, Rueth NM, Hodges JS, Habermann EB, Andrade RS, D’Cunha J,
Maddaus MA: Conditional cancer-specific versus cardiovascular-specific
survival after lobectomy for stage I non-small cell lung cancer. Ann
Thorac Surg 2010, 90:375-382.
21. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk
factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
doi:10.1186/1749-8090-7-4
Cite this article as: Imperatori et al.: Atrial fibrillation after pulmonary
lobectomy for lung cancer affects long-term survival in a prospective
single-center study. Journal of Cardiothoracic Surgery 2012 7:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Imperatori et al. Journal of Cardiothoracic Surgery 2012, 7:4
http://www.cardiothoracicsurgery.org/content/7/1/4
Page 8 of 8
